{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T19:05:12Z","timestamp":1774983912898,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,11,10]],"date-time":"2011-11-10T00:00:00Z","timestamp":1320883200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1007\/s11899-011-0102-1","type":"journal-article","created":{"date-parts":[[2011,11,9]],"date-time":"2011-11-09T12:12:30Z","timestamp":1320840750000},"page":"43-49","source":"Crossref","is-referenced-by-count":20,"title":["Prognostication in Primary Myelofibrosis"],"prefix":"10.1007","volume":"7","author":[{"given":"Francisco","family":"Cervantes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arturo","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,11,10]]},"reference":[{"issue":"114","key":"102_CR1","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"30","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;30(114):937\u201351.","journal-title":"Blood"},{"key":"102_CR2","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/leu.2010.69","volume":"24","author":"A Tefferi","year":"2010","unstructured":"Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 2010;24:1128\u201338.","journal-title":"Leukemia"},{"key":"102_CR3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/MOH.0b013e328343998e","volume":"18","author":"O Abdel-Wahab","year":"2011","unstructured":"Abdel-Wahab O. Genetics of the myeloproliferative neoplasms. Curr Opin Hematol. 2011;18:117\u201323.","journal-title":"Curr Opin Hematol"},{"key":"102_CR4","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1182\/blood-2011-02-292102","volume":"118","author":"W Vainchenker","year":"2011","unstructured":"Vainchenker W, Delhommeau F, Constantinescu SN, Bernard O-A. New mutations and pathogenesis of myeloproliferative neoplasms. Blood. 2011;118:1723\u201335.","journal-title":"Blood"},{"key":"102_CR5","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"\u2022 Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113:2895\u2013901. Based on more than 1,000 PMF patients from several European and American centers, this study by the IWG-MRT defined the first International Prognostic Scoring System (IPSS) for primary myelofibrosis. The IPSS demonstrated high discriminating power and predictive accuracy, and could be reproduced after discounting the demographic factors related to the patients\u2019 age, sex, period of diagnosis, and country of origin.","journal-title":"Blood"},{"key":"102_CR6","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1056\/NEJM200004273421706","volume":"342","author":"A Tefferi","year":"2000","unstructured":"Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med. 2000;342:1255\u201365.","journal-title":"N Engl J Med"},{"key":"102_CR7","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1182\/blood-2010-11-315614","volume":"117","author":"A Tefferi","year":"2011","unstructured":"Tefferi A. How I treat myelofibrosis. Blood. 2011;117:3494\u2013504.","journal-title":"Blood"},{"key":"102_CR8","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/cncr.22630","volume":"109","author":"A Tefferi","year":"2007","unstructured":"Tefferi A, Huang J, Schwager S, et al. Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution. Cancer. 2007;109:2083\u20138.","journal-title":"Cancer"},{"key":"102_CR9","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1182\/blood-2009-12-255943","volume":"115","author":"P Morel","year":"2010","unstructured":"\u2022 Morel P, Duhamel A, Hivert B, et al. Identification during the follow-up of time-dependent prognostic factors for the competing risks of death and blast phase in primary myelofibrosis: a study of 172 patients. Blood. 2010;115:4350\u20135. These authors rely on competing risk analysis to investigate factors predicting leukemic transformation in PMF.","journal-title":"Blood"},{"key":"102_CR10","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","volume":"29","author":"N Gangat","year":"2011","unstructured":"\u2022 Gangat N, Caramazza D, Vaidya R. DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29:392\u20137. These authors show that thrombocytopenia, transfusion need, and some definite cytogenetic abnormalities allow further refinement of the DIPSS.","journal-title":"J Clin Oncol"},{"key":"102_CR11","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.4065\/mcp.2009.0543","volume":"84","author":"R Vaidya","year":"2009","unstructured":"Vaidya R, Siragusa S, Huang J, et al. Mature survival data for 176 patients younger than 60\u00a0years with primary myelofibrosis diagnosed between 1976 and 2005: evidence for survival gains in recent years. Mayo Clin Proc. 2009;84:1114\u20139.","journal-title":"Mayo Clin Proc"},{"key":"102_CR12","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/leu.2008.72","volume":"22","author":"F Cervantes","year":"2008","unstructured":"Cervantes F, Passamonti F, Barosi G. Life expectancy and prognostic factors in the classic BCR\/ABL-negative myeloproliferative disorders. Leukemia. 2008;22:905\u201314.","journal-title":"Leukemia"},{"key":"102_CR13","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1046\/j.1365-2141.1997.1722990.x","volume":"98","author":"JT Reilly","year":"1997","unstructured":"Reilly JT, Snowden JA, Spearing RL, et al. Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases. Br J Haematol. 1997;98:96\u2013102.","journal-title":"Br J Haematol"},{"key":"102_CR14","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood.V88.3.1013.1013","volume":"88","author":"B Dupriez","year":"1996","unstructured":"Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood. 1996;88:1013\u20138.","journal-title":"Blood"},{"key":"102_CR15","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","volume":"115","author":"F Passamonti","year":"2010","unstructured":"\u2022 Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115:1703\u20138. This study builds on previous research by the IWG-MRT to show how the acquisition of the IPSS poor prognosis factors during the course of PMF (dynamic IPSS or DIPSS) allows dynamic prediction of the patients\u2019 remaining life expectancy.","journal-title":"Blood"},{"key":"102_CR16","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1046\/j.1365-2141.1997.782714.x","volume":"97","author":"F Cervantes","year":"1997","unstructured":"Cervantes F, Pereira A, Esteve J, et al. Identification of \u2018short-lived\u2019 and \u2018long-lived\u2019 patients at presentation of idiopathic myelofibrosis. Br J Haematol. 1997;97:635\u201340.","journal-title":"Br J Haematol"},{"key":"102_CR17","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1046\/j.1365-2141.1998.00833.x","volume":"102","author":"F Cervantes","year":"1998","unstructured":"Cervantes F, Barosi G, Demory JL, et al. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol. 1998;102:684\u201390.","journal-title":"Br J Haematol"},{"key":"102_CR18","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1365-2141.1988.tb02507.x","volume":"70","author":"G Barosi","year":"1988","unstructured":"Barosi G, Berzuini C, Liberato LN, et al. A prognostic classification of myelofibrosis with myeloid metaplasia. Br J Haematol. 1988;70:397\u2013401.","journal-title":"Br J Haematol"},{"key":"102_CR19","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1365-2141.1990.tb02609.x","volume":"75","author":"G Visani","year":"1990","unstructured":"Visani G, Finelli C, Castelli U, et al. Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematol. 1990;75:4\u20139.","journal-title":"Br J Haematol"},{"key":"102_CR20","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","volume":"29","author":"A Tefferi","year":"2011","unstructured":"Tefferi A, Vaidya R, Caramazza D, et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in Primary Myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol. 2011;29:1356\u201363.","journal-title":"J Clin Oncol"},{"key":"102_CR21","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/ajh.21391","volume":"84","author":"A Tefferi","year":"2009","unstructured":"Tefferi A, Mesa RA, Pardanani A, et al. Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not. Am J Hematol. 2009;84:265\u20137.","journal-title":"Am J Hematol"},{"key":"102_CR22","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/ajh.21730","volume":"85","author":"A Tefferi","year":"2010","unstructured":"Tefferi A, Siragusa S, Hussein K, et al. Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis\u2013prognostic relevance is independent of IPSS or karyotype. Am J Hematol. 2010;85:14\u20137.","journal-title":"Am J Hematol"},{"key":"102_CR23","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3324\/haematol.2010.031831","volume":"96","author":"C Elena","year":"2011","unstructured":"Elena C, Passamonti F, Rumi E, et al. Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS. Haematologica. 2011;96:167\u201370.","journal-title":"Haematologica"},{"key":"102_CR24","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ajh.21959","volume":"86","author":"A Pereira","year":"2011","unstructured":"Pereira A, Nomdedeu M, Aguilar JL, et al. Transfusion intensity, not the cumulative red blood cell transfusion burden, determines the prognosis of patients with myelodysplastic syndrome on chronic transfusion support. Am J Hematol. 2011;86:245\u201350.","journal-title":"Am J Hematol"},{"key":"102_CR25","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1182\/blood.V98.12.3249","volume":"98","author":"G Barosi","year":"2001","unstructured":"Barosi G, Viarengo G, Pecci A, et al. Diagnostic and clinical relevance of the number of circulating CD34 + cells in myelofibrosis with myeloid metaplasia. Blood. 2001;98:3249\u201355.","journal-title":"Blood"},{"key":"102_CR26","first-page":"1204","volume":"88","author":"V Sagaster","year":"2003","unstructured":"Sagaster V, Jager E, Weltermann A, et al. Circulating hematopoietic progenitor cells predict survival in patients with myelofibrosis with myeloid metaplasia. Haematologica. 2003;88:1204\u201312.","journal-title":"Haematologica"},{"key":"102_CR27","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1365-2141.2004.05280.x","volume":"128","author":"B Arora","year":"2004","unstructured":"Arora B, Sirhan S, Hover JD, et al. Peripheral blood CD34 count in myelofibrosis with myeloid metaplasia: a prospective evaluation of prognostic value in 94 patients. Br J Haematol. 2004;128:42\u20138.","journal-title":"Br J Haematol"},{"key":"102_CR28","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1182\/blood.V96.10.3374","volume":"96","author":"RA Mesa","year":"2000","unstructured":"Mesa RA, Hanson CA, Rajkumar SV, et al. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasma. Blood. 2000;96:3374\u201380.","journal-title":"Blood"},{"key":"102_CR29","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1600-0609.1990.tb00357.x","volume":"44","author":"A Pereira","year":"1990","unstructured":"Pereira A, Cervantes F, Brugues R, Rozman C. Bone marrow histopathology in primary myelofibrosis: clinical and haematologic correlations and prognostic evaluation. Eur J Haematol. 1990;44:95\u20139.","journal-title":"Eur J Haematol"},{"key":"102_CR30","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1182\/blood-2008-09-178541","volume":"113","author":"CS Tam","year":"2009","unstructured":"Tam CS, Abruzzo LV, Lin KI, et al. The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course. Blood. 2009;113:4171\u20138.","journal-title":"Blood"},{"key":"102_CR31","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/j.1600-0609.2009.01298.x","volume":"83","author":"T Hidaka","year":"2009","unstructured":"Hidaka T, Slide K, Shimoda H, et al. The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan. Eur J Haematol. 2009;83:328\u201333.","journal-title":"Eur J Haematol"},{"key":"102_CR32","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood-2009-08-240135","volume":"115","author":"K Hussein","year":"2010","unstructured":"Hussein K, Pardanani AD, Van Dyke DL, et al. International prognostic scoring system-independent cytogenetic risk categorization in primary myelofibrosis. Blood. 2010;115:496\u20139.","journal-title":"Blood"},{"key":"102_CR33","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/leu.2010.234","volume":"25","author":"D Caramazza","year":"2011","unstructured":"\u2022 Caramazza D, Begna KH, Gangat N, et al. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Leukemia. 2011;25;82\u20138. Until now, this is the largest study on the prognostic significance of karyotype abnormalities in PMF.","journal-title":"Leukemia"},{"key":"102_CR34","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1046\/j.1365-2141.2001.02796.x","volume":"113","author":"A Tefferi","year":"2001","unstructured":"Tefferi A, Mesa RA, Schroeder G, et al. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br J Haematol. 2001;113:763\u201371.","journal-title":"Br J Haematol"},{"key":"102_CR35","doi-asserted-by":"crossref","first-page":"5612","DOI":"10.1182\/blood-2010-11-320002","volume":"117","author":"R Vaidya","year":"2011","unstructured":"\u2022 Vaidya R, Caramazza D, Begna KH, et al. Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival. Blood. 2011;117:5612\u20135. This study identifies monosomal karyotype, which is present in about 2% of PMF patients, as a strong predictor of extremely short survival and high risk of leukemic transformation.","journal-title":"Blood"},{"key":"102_CR36","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.blre.2010.10.004","volume":"25","author":"FPS Santos","year":"2011","unstructured":"Santos FPS, Verstovsek S. JAK2 inhibitors: what\u2019s the true potential? Blood Rev. 2011;25:53\u201363.","journal-title":"Blood Rev"},{"key":"102_CR37","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood-2005-08-3395","volume":"107","author":"PJ Campbell","year":"2006","unstructured":"Campbell PJ, Griesshammer M, D\u00f6hner K, et al. V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood. 2006;107:2098\u2013100.","journal-title":"Blood"},{"key":"102_CR38","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1182\/blood-2007-07-099184","volume":"110","author":"G Barosi","year":"2007","unstructured":"Barosi G, Bergamaschi G, Marchetti M, et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood. 2007;110:430\u20136.","journal-title":"Blood"},{"key":"102_CR39","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/sj.leu.2405097","volume":"22","author":"A Tefferi","year":"2008","unstructured":"Tefferi A, Lasho TL, Huang J, et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia. 2008;22:756\u201361.","journal-title":"Leukemia"},{"key":"102_CR40","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1182\/blood-2009-04-216044","volume":"114","author":"P Guglielmelli","year":"2009","unstructured":"Guglielmelli P, Barosi G, Specchia G, et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood. 2009;114:1477\u201383.","journal-title":"Blood"},{"key":"102_CR41","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1002\/cncr.23505","volume":"112","author":"J Huang","year":"2008","unstructured":"Huang J, Li C-Y Li, Mesa RA, et al. Risk factors for leukemic transformation in patients with primary myelofibrosis. Cancer. 2008;112:2726\u201332.","journal-title":"Cancer"},{"key":"102_CR42","doi-asserted-by":"crossref","first-page":"5587","DOI":"10.1200\/JCO.2009.22.8833","volume":"27","author":"CS Tam","year":"2009","unstructured":"Tam CS, Kantarjian H, Cortes J, et al. Dynamic model for predicting death within 12\u00a0months in patients with primary or post\u2013polycythemia vera\/essential thrombocythemia myelofibrosis. J Clin Oncol. 2009;27:5587\u201393.","journal-title":"J Clin Oncol"},{"key":"102_CR43","doi-asserted-by":"crossref","unstructured":"Pardanani A, Guglielmelli P, Lasho TL, et al. Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients Leukemia. 2011 Jun 21 (Epub ahead of print). doi: 10.1038\/leu.2011.161","DOI":"10.1038\/leu.2011.161"},{"key":"102_CR44","first-page":"3630","volume":"91","author":"G Barosi","year":"1998","unstructured":"Barosi G, Ambrosetti A, Centra A, et al. Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Italian Cooperative Study Group on Myeloid with Myeloid Metaplasia. Blood. 1998;91:3630\u20136.","journal-title":"Blood"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-011-0102-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-011-0102-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-011-0102-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T08:41:09Z","timestamp":1593247269000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-011-0102-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,10]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["102"],"URL":"https:\/\/doi.org\/10.1007\/s11899-011-0102-1","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,10]]}}}